carfilzomib

Leah SherwoodMyeloma | November 16, 2022
Carfilzomib, lenalidomide, and dexamethasone improved progression-free survival (PFS) over...
Leah SherwoodMyeloma | November 16, 2022
The ORR was 96%, including 92% at the level of VGPR, and the MRD negativity rate was 62%...
Leah LawrenceMyeloma | November 22, 2022
In myeloma, isatuximab plus carfilzomib and dexamethasone (Isa-Kd) resulted in clinically improved...
Advertisement
Leah LawrenceMyeloma | February 3, 2023
The median PFS with the three-drug combination was higher compared with carfilzomib and dexamethasone alone.
Advertisement
Advertisement
Advertisement